Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A1 | P04798 | 17/20 | 0.53 |
| ▸ | CYP1B1 | Q16678 | 17/20 | 0.53 |
| ▸ | MAOB | P27338 | 2/20 | 0.44 |
| ▸ | DPP4 | P27487 | 1/20 | 0.44 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.44 |
| ▸ | P4HB | P07237 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1935354 | 1.00 | CYP1A1 (0.53) | CYP1A1CYP1B1MAOBDPP4CXCL12 | |
| SCHEMBL3964836 | 0.88 | ALDH1A1 (0.48) | CYP1A1CYP1B1MAOBCXCL12 | |
| SCHEMBL15361865 | 0.88 | CYP1A1 (0.49) | CYP1A1CYP1B1MAOBDPP4CXCL12 | |
| SCHEMBL29381917 | 0.88 | CYP1A1 (0.49) | CYP1A1CYP1B1MAOBDPP4CXCL12 | |
| SCHEMBL1933383 | 0.88 | CYP1A1 (0.39) | CYP1A1CYP1B1MAOB | |
| SCHEMBL29382056 | 0.88 | CYP1A1 (0.39) | CYP1A1CYP1B1MAOB | |
| SCHEMBL3969812 | 0.87 | CAPN1 (0.45) | MAOBDPP4 | |
| SCHEMBL3962833 | 0.87 | PPARG (0.38) | CYP1A1CYP1B1 | |
| SCHEMBL3972097 | 0.86 | LMNA (0.46) | CXCL12 | |
| SCHEMBL498833 | 0.86 | MAPT (0.44) | CYP1B1MAOBCXCL12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113677336-B | Combination therapy comprising a compound of formula (I) and a GLP-1 receptor agonist | 基恩菲特公司 | 2024-04-30 | — | — | CN | disclosed |
| CN-111065748-B | Non-invasive diagnosis of non-alcoholic fatty liver disease, non-alcoholic steatohepatitis and/or liver fibrosis | 基恩菲特公司 | 2024-04-09 | — | — | CN | disclosed |
| CN-109072302-B | Non-invasive diagnosis of non-alcoholic steatohepatitis | 基恩菲特公司 | 2024-01-16 | — | — | CN | disclosed |
| CN-108138232-B | Methods for diagnosing and assessing non-alcoholic steatohepatitis | 基恩菲特公司 | 2023-07-18 | — | — | CN | disclosed |
| CN-110536682-B | Combinations of eprinox or a derivative thereof with anti-NASH, anti-fibrosis or anti-cholestasis agents | 基恩菲特公司 | 2023-01-06 | — | — | CN | disclosed |
| US-20220411874-A1 | METHODS FOR DIAGNOSING AND EVALUATING NON-ALCOHOLIC STEATOHEPATITIS | GENFIT (FR) | 2022-12-29 | — | — | US | disclosed |
| US-11519034-B2 | Non-invasive diagnostic of non-alcoholic fatty liver diseases, non-alcoholic steatohepatitis and/or liver fibrosis | GENFIT (FR) | 2022-12-06 | — | — | US | disclosed |
| CN-110198708-B | Pharmaceutical compositions for combination therapy | 基恩菲特公司 | 2022-09-20 | — | — | CN | disclosed |
| EP-3980070-A1 | METHOD FOR TREATMENT OF AT RISK PATIENTS | Genfit (FR) | 2022-04-13 | — | — | EP | disclosed |
| EP-3952855-A1 | COMBINATION THERAPY COMPRISING COMPOUNDS OF FORMULA (I) AND GLP-1 RECEPTOR AGONISTS | Genfit (FR) | 2022-02-16 | — | — | EP | disclosed |
| EP-3952868-A1 | COMBINATION OF NITAZOXANIDE AND ELAFIBRANOR FOR THE TREATMENT OF IMMUNE DISEASES OR INFLAMMATION | Genfit (FR) | 2022-02-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220411874-A1 | METHODS FOR DIAGNOSING AND EVALUATING NON-ALCOHOLIC STEATOHEPATITIS | APOB, IL33, IL36G | CYP1A1 3428/4885CYP1B1 3157/4885MAOB 2900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.